人类微生物组衍生药物与诊断：全球市场

全球人类微生物组衍生药物和诊断市场预计将从 2025 年的 3.934 亿美元成长到 2030 年底的 12 亿美元，2025 年至 2030 年的复合年增长率为 25.6%。

预计北美市场规模将从 2025 年的 2.257 亿美元成长到 2030 年底的 5.789 亿美元，同期的复合年增长率为 20.7%。

预计欧洲市场规模将从 2025 年的 6,930 万美元成长到 2030 年底的 3.059 亿美元，同期的复合年增长率为 34.6%。

本报告调查了全球人类微生物组衍生药物和诊断药物市场，并提供了市场概况摘要、市场影响因素和市场机会分析、法律制度、新兴技术和技术发展趋势、市场规模趋势和预测、各个细分市场和地区的详细分析、竞争格局以及主要企业的概况。

目录

第一章执行摘要

• 市场展望
• 研究范围
• 市场摘要
• 市场动态
• 新兴技术
• 細項分析
• 区域分析
• 结论

第二章 市场概述

• 概述和市场定义
• 人类的不同微生物群
• 微生物组与人类健康与疾病的关係
• 支持微生物组研究的技术
• 栽培与栽培技术
• 微生物组疗法的发展策略
• 添加微生物组疗法
• 调节微生物组疗法
• 宏观经济因素分析
• 地缘政治因素
• 通货膨胀和外汇波动
• 波特五力分析

第三章 市场动态

• 摘要
• 市场驱动因素
• 越来越多的证据显示微生物组与疾病之间存在相关性
• 基于微生物组的疾病预防和监测诊断
• 市场限制
• 临床试验设计的挑战
• 缺乏既定的法规结构
• 微生物组疗法的高成本
• 市场机会
• 直接面向消费者的微生物组检测的兴起
• 针对肺部和皮肤微生物组的药物和诊断方法

第四章 监管情况

• 监管方面
• 北美洲
• 欧洲
• 亚太地区

第五章 新兴技术

• 摘要
• 新兴技术
• 微生物生态系疗法
• 宏转录定序
• 基因改造微生物组疗法
• 微生物组衍生药物的联合治疗疗法和辅助性治疗
• 新型临床前模型

第六章市场区隔分析

• 细分市场
• 按类型进行市场分析
• 基于微生物组的医学
• 市场分析：按应用
• 感染疾病
• 消化系统疾病
• 代谢紊乱
• 癌症
• 其他的
• 最终用户的市场分析
• 医院和诊所
• 研究所
• 製药公司
• 地理分布
• 市场分析：按地区
• 北美洲
• 欧洲
• 亚太地区
• 南美洲
• 中东和非洲

第七章 竞争讯息

• 摘要
• 企业市场占有率分析
• 竞争分析
• 创业融资及投资环境
  • 近期动态

第八章 基于人类微生物组的製药和诊断行业的永续性：ESG 视角

• ESG：简介
• ESG风险评估
• 结论

第九章 附录

• 调查方法
• 来源
• 简称
• 公司简介
• BIOMEBANK
• ENTEROBIOTIX LTD.
• ENTEROME
• FERRING
• GENETIC ANALYSIS
• ILLUMINA INC.
• MICROBIOME INSIGHTS
• MICROBIOTICA
• NESTLE HEALTH SCIENCE
• OXFORD NANOPORE TECHNOLOGIES PLC
• PACBIO
• SFA THERAPEUTICS INC.
• THERMO FISHER SCIENTIFIC INC.
• VEDANTA BIOSCIENCES INC.

The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.

The North American market for human microbiome-based drugs and diagnostics is expected to grow from $225.7 million in 2025 to reach $578.9 million by the end of 2030, at a CAGR of 20.7% from 2025 through 2030.

The European market for human microbiome-based drugs and diagnostics is expected to grow from $69.3 million in 2025 to reach $305.9 million by the end of 2030, at a CAGR of 34.6% from 2025 through 2030.

Report Scope

The report analyzes the global market for human microbiome-based drugs and diagnostics and market trends. It includes global revenues for the base year 2024, estimated data for 2025 and the compound annual growth rates (CAGRs) for forecast period of 2025 to 2030. The market is segmented by type, application, end user and region. The microbiome-based drug segment is further segmented by route of administration: oral or rectal. Microbiome-based diagnostics are segmented based on product type into instruments, and reagents and kits. End-user segments include hospitals and clinics, pharmaceutical companies and research institutes. Applications include metabolic, gastrointestinal (GI) and infectious diseases, cancer and others. The regions covered include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA). The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) developments.

Human microbiome-based products that are intended for wellness or as dietary supplements are outside the scope of the report, as are nonstandardized fecal microbiota transplantation (FMT) procedures. Microbiome-based diagnostics include only products that claim to detect or screen for any disease or condition.

Report Includes

• 55 data tables and 51 additional tables
• Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region
• Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables
• Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments
• An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development
• Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
• An analysis of the key patent grants and recently published patents
• Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook
• Profiles of the leading companies, including Ferring Pharmaceuticals, Nestle Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics
• Emerging Technologies
• Analysis by Segment
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview and Market Definition
• Different Microbiomes in Humans
• Microbiome, Human Health and Disease
• Technologies Aiding Microbiome Research
• Culturing and Cultivation
• Strategies for the Development of Microbiome Therapeutics
• Additive Microbiome Therapy
• Modulatory Microbiome Therapy
• Analysis of Macroeconomic Factors
• Geopolitical Factors
• Inflation and Currency Exchange Fluctuations
• Porter's Five Forces Analysis

Chapter 3 Market Dynamics

• Takeaways
• Market Drivers
• Growing Evidence of Microbiome-disease Correlation
• Microbiome-based Diagnostics for Disease Prevention and Monitoring
• Market Restraints
• Challenges in Clinical Trial Design
• Lack of Established Regulatory Frameworks
• High Costs of Microbiome Therapeutics
• Market Opportunities
• Direct-to-Consumer Microbiome Testing
• Drugs and Diagnostics for Lung and Skin Microbiomes

Chapter 4 Regulatory Landscape

• Regulatory Aspects
• North America
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies

• Takeaways
• Emerging Technologies
• Microbial Ecosystem Therapeutics
• Metatranscriptome Sequencing
• Genetically Modified Microbiome Therapeutics
• Combination and Adjuvant Therapies with Microbiome-based Drugs
• Novel Preclinical Models

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis by Type
• Microbiome-based Drugs
• Market Analysis by Application
• Infectious Diseases
• GI Disorders
• Metabolic Disorders
• Cancer
• Other Diseases
• Market Analysis by End User
• Hospitals and Clinics
• Research Institutions
• Pharmaceutical Companies
• Geographic Breakdown
• Market Analysis by Region
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Chapter 7 Competitive Intelligence

• Takeaways
• Company Share Analysis
• Competitive Analysis
• Venture Funding and Investment Landscape
• Recent Developments

Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective

• Introduction to ESG
• ESG Risk Ratings
• Concluding Remarks

Chapter 9 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• BIOMEBANK
• ENTEROBIOTIX LTD.
• ENTEROME
• FERRING
• GENETIC ANALYSIS
• ILLUMINA INC.
• MICROBIOME INSIGHTS
• MICROBIOTICA
• NESTLE HEALTH SCIENCE
• OXFORD NANOPORE TECHNOLOGIES PLC
• PACBIO
• SFA THERAPEUTICS INC.
• THERMO FISHER SCIENTIFIC INC.
• VEDANTA BIOSCIENCES INC.
• Emerging Start-ups/Market Disruptors

List of Tables

• Summary Table : Global Market for Human Microbiome-based Drugs and Diagnostics, by Region, Through 2030
• Table 1 : Technology for Microbiome Research
• Table 2 : Diseases Associated with Microbiome Dysbiosis
• Table 3 : Microbiome-based Drug Nomenclature
• Table 4 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
• Table 5 : Global Market for Human Microbiome-based Drugs, by Route of Administration, Through 2030
• Table 6 : Global Market for Human Microbiome-based Drugs, by Region, Through 2030
• Table 7 : Global Market for Human Microbiome-based Drugs, by Rectal Route of Administration, by Region, Through 2030
• Table 8 : Global Market for Human Microbiome-based Drugs, by Oral Route of Administration, by Region, Through 2030
• Table 9 : Global Market for Human Microbiome-based Diagnostics, by Region, Through 2030
• Table 10 : Global Market for Human Microbiome-based Diagnostics, by Product Type, Through 2030
• Table 11 : Global Market for Human Microbiome-based Diagnostics Reagents and Kits, by Region, Through 2030
• Table 12 : Global Market for Human Microbiome-based Diagnostic Instruments, by Region, Through 2030
• Table 13 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Application, Through 2030
• Table 14 : Global Market for Human Microbiome-based Drugs and Diagnostics for Infectious Diseases, by Region, Through 2030
• Table 15 : Global Market for Human Microbiome-based Drugs and Diagnostics for GI Disorders, by Region, Through 2030
• Table 16 : Global Market for Human Microbiome-based Drugs and Diagnostics for Metabolic Disorders, by Region, Through 2030
• Table 17 : Global Market for Human Microbiome-based Drugs and Diagnostics for Cancer, by Region, Through 2030
• Table 18 : Microbiome-based Drugs in the Pipeline for Cancer Therapy
• Table 19 : Global Market for Human Microbiome-based Drugs and Diagnostics for Other Diseases, by Region, Through 2030
• Table 20 : Global Market for Human Microbiome-based Drugs and Diagnostics, by End User, Through 2030
• Table 21 : Global Market for Microbiome-based Drugs and Diagnostics for Hospitals and Clinics, by Region, Through 2030
• Table 22 : Global Market for Microbiome-based Drugs and Diagnostics for Research Institutions, by Region, Through 2030
• Table 23 : Global Market for Microbiome-based Drugs and Diagnostics for Pharmaceutical Firms, by Region, Through 2030
• Table 24 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Region, Through 2030
• Table 25 : North American Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
• Table 26 : North American Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
• Table 27 : North American Market for Microbiome-based Drugs, by Route of Administration, Through 2030
• Table 28 : North American Market for Microbiome-based Diagnostics, by Product Type, Through 2030
• Table 29 : North American Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
• Table 30 : North American Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
• Table 31 : European Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
• Table 32 : European Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
• Table 33 : European Market for Microbiome-based Drugs, by Route of Administration, Through 2030
• Table 34 : European Market for Microbiome-based Diagnostics, by Product Type, Through 2030
• Table 35 : European Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
• Table 36 : European Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
• Table 37 : Asia-Pacific Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
• Table 38 : Asia-Pacific Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
• Table 39 : Asia-Pacific Market for Microbiome-based Drugs, by Route of Administration, Through 2030
• Table 40 : Asia-Pacific Market for Microbiome-based Diagnostics, by Product Type, Through 2030
• Table 41 : Asia-Pacific Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
• Table 42 : Asia-Pacific Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
• Table 43 : South American Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
• Table 44 : South American Market for Microbiome-based Drugs, by Route of Administration, Through 2030
• Table 45 : South American Market for Microbiome-based Diagnostics, by Product Type, Through 2030
• Table 46 : South American Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
• Table 47 : South American Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
• Table 48 : MEA Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
• Table 49 : MEA Market for Microbiome-based Drugs, by Administration Route, Through 2030
• Table 50 : MEA Market for Microbiome-based Diagnostics, by Product Type, Through 2030
• Table 51 : MEA Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
• Table 52 : MEA Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
• Table 53 : Competitive Analysis of Human Microbiome-based Diagnostics Market
• Table 54 : Venture Funding in the Human Microbiome-based Drugs and Diagnostics Market, 2024
• Table 55 : Recent Developments in the Human Microbiome-based Drug and Diagnostics Market, 2022-2025
• Table 56 : ESG Goals of Human Microbiome-based Drugs and Diagnostics Companies
• Table 57 : ESG Risk Ratings for Human Microbiome-based Drugs and Diagnostics Firms, 2025
• Table 58 : Report Information Sources
• Table 59 : Abbreviations Used in this Report
• Table 60 : BiomeBank: Company Snapshot
• Table 61 : BiomeBank: Product Portfolio
• Table 62 : BiomeBank: News/Key Developments, 2024
• Table 63 : EnteroBiotix Ltd.: Company Snapshot
• Table 64 : EnteroBiotix Ltd.: Product Portfolio
• Table 65 : EnteroBiotix Ltd.: News/Key Developments, 2024
• Table 66 : Enterome: Company Snapshot
• Table 67 : Enterome: Product Portfolio
• Table 68 : Enterome: News/Key Developments, 2022
• Table 69 : Ferring: Company Snapshot
• Table 70 : Ferring: Financial Performance, FY 2022 and 2023
• Table 71 : Ferring: Product Portfolio
• Table 72 : Ferring: News/Key Developments, 2022 and 2023
• Table 73 : Genetic Analysis: Company Snapshot
• Table 74 : Genetic Analysis: Financial Performance, FY 2023 and 2024
• Table 75 : Genetic Analysis: Product Portfolio
• Table 76 : Genetic Analysis: News/Key Developments, 2024
• Table 77 : Illumina Inc.: Company Snapshot
• Table 78 : Illumina Inc.: Financial Performance, FY 2023 and 2024
• Table 79 : Illumina Inc.: Product Portfolio
• Table 80 : Microbiome Insights: Company Snapshot
• Table 81 : Microbiome Insights: Product Portfolio
• Table 82 : Microbiome Insights: News/Key Developments, 2024
• Table 83 : Microbiotica: Company Snapshot
• Table 84 : Microbiotica: Product Portfolio
• Table 85 : Microbiotica: News/Key Developments, 2023
• Table 86 : Nestle Health Science: Company Snapshot
• Table 87 : Nestle Health Science: Product Portfolio
• Table 88 : Nestle Health Science: News/Key Developments, 2024
• Table 89 : Oxford Nanopore Technologies plc: Company Snapshot
• Table 90 : Oxford Nanopore Technologies plc: Financial Performance, FY 2023 and 2024
• Table 91 : Oxford Nanopore Technologies plc.: Product Portfolio
• Table 92 : PacBio: Company Snapshot
• Table 93 : PacBio: Financial Performance, FY 2023 and 2024
• Table 94 : PacBio: Product Portfolio
• Table 95 : PacBio: News/Key Developments, 2025
• Table 96 : SFA Therapeutics Inc.: Company Snapshot
• Table 97 : SFA Therapeutics Inc.: Product Portfolio
• Table 98 : SFA Therapeutics Inc.: News/Key Developments, 2024
• Table 99 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 100 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
• Table 101 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 102 : Vedanta Biosciences Inc.: Company Snapshot
• Table 103 : Vedanta Biosciences Inc.: Product Portfolio
• Table 104 : Vedanta Biosciences Inc.: News/Key Developments, 2023
• Table 105 : Emerging Startups

List of Figures

• Summary Figure : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Region, 2024
• Figure 1 : Essential Functions of the Human Microbiome
• Figure 2 : Porter's Five Forces Analysis of the Human Microbiome-based Drugs and Diagnostics Market
• Figure 3 : Human Microbiome-based Drugs and Diagnostics Market Dynamics
• Figure 4 : Diseases and Conditions Associated with Dysbiosis
• Figure 5 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Type, 2024
• Figure 6 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Application, 2024
• Figure 7 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by End User, 2024
• Figure 8 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Region, 2024
• Figure 9 : North American Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
• Figure 10 : European Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
• Figure 11 : Asia-Pacific Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
• Figure 12 : Company Shares in the Human Microbiome-based Drug Market, 2024
• Figure 13 : Ferring: Revenue Share, by Business Unit, FY 2023
• Figure 14 : Ferring: Revenue Share, by Country/Region, FY 2023
• Figure 15 : Genetic Analysis: Revenue Share, by Business Unit, FY 2024
• Figure 16 : Genetic Analysis: Revenue Share, by Country/Region, FY 2024
• Figure 17 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 18 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 19 : Oxford Nanopore Technologies plc: Revenue Share, by Business Unit, FY 2024
• Figure 20 : Oxford Nanopore Technologies plc: Revenue Share, by Country/Region, FY 2024
• Figure 21 : PacBio: Revenue Share, by Business Unit, FY 2024
• Figure 22 : PacBio: Revenue Share, by Country/Region, FY 2024
• Figure 23 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 24 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024